Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 6th June 2023
This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-system interactions. We cover the role of AI Daily Roundup and its application in various industries and daily lives.
UpdateAI Lands $2.3 Million to Ignite Customer Success with Cutting-Edge AI Technology
UpdateAI, the ChatGPT-powered Customer Success platform that generates Smart Summaries of customer meeting notes and automates CS follow-up workflow, announced it has raised a $2.3 million funding round led by IdealabX. Stage Venture Partners, Zoom Ventures, a16z’s scout fund and Howard Morgan also participated in the round. UpdateAI previously raised $1.7 million, bringing its total financing to $4 million.
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
BenevolentAI , a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.
FPT and Mila Renew Strategic Partnership, Advancing Responsible AI
FPT, Vietnam’s largest IT service provider, and Mila, Quebec Artificial Intelligence Institute, announced the renewal of a three-year strategic partnership agreement.
BrainChip Holdings Ltd , a global leader in neuromorphic artificial intelligence (AI) IP, and Lorser Industries ., a leading provider of system-level manufacturing and integration, announced the companies will use BrainChip’s Akida technology to deliver neuromorphic computing solutions for software-defined radio (SDR) devices.
Massive Bio, a globally recognized leader in the oncology space, has proudly announced its appointment as a founding member of CancerX, a groundbreaking initiative endorsed by The White House. This appointment situates Massive Bio at the forefront of a national public-private partnership aiming to revolutionize the fight against cancer. Spearheaded by the rejuvenated Cancer Moonshot initiative, CancerX is co-hosted by Moffitt Cancer Center and Digital Medicine Society (DiMe), bringing together diverse stakeholders to foster greater equity and reduce financial toxicity in cancer care and research.
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.